RO5093151

DRUG5 trials

Sponsors

Hoffmann-La Roche

Conditions

Diabetes Mellitus Type 2Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGlaucomaHealthy VolunteerHypertension, Glaucoma, Open-Angle

Phase 1

A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

CompletedNCT01277094

Hoffmann-La RocheFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Start: 2011-04-30End: 2012-03-31Updated: 2016-11-02

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

CompletedNCT01591850

Hoffmann-La RocheHealthy Volunteer

Start: 2011-09-30End: 2011-11-30Updated: 2016-11-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

CompletedNCT02622334

Hoffmann-La RocheGlaucoma

Start: 2015-12-29End: 2016-07-28Updated: 2018-03-14

Phase 2

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

CompletedNCT00823680

Hoffmann-La RocheDiabetes Mellitus Type 2

Start: 2009-04-30End: 2009-08-31Updated: 2016-07-28

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

CompletedNCT01493271

Hoffmann-La RocheHypertension, Glaucoma, Open-Angle

Start: 2011-12-31End: 2012-11-30Updated: 2016-11-02

Related Papers

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.

2014-02-1785 citations